Cerebral toxoplasmosis after rituximab for pemphigus vulgaris
| Autor: | Kiran Motaparthi, Noura Ayoubi, Vidhu Kariyawasam, Erica B. Lee, Mehmet S. Albayram |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
pemphigus vulgaris
Mucocutaneous zone TMP-SMX trimethoprim-sulfamethoxazole Case Report Dermatology CNS central nervous system progressive multifocal leukoencephalopathy CSF cerebrospinal fluid 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine rituximab immune system diseases Prednisone hemic and lymphatic diseases PML progressive multifocal leukoencephalopathy medicine Adverse effect CD20 Cerebral toxoplasmosis biology business.industry Progressive multifocal leukoencephalopathy Pemphigus vulgaris medicine.disease Toxoplasmosis PV pemphigus vulgaris 030220 oncology & carcinogenesis Immunology biology.protein Rituximab MMF mycophenolate mofetil business MRI magnetic resonance imaging medicine.drug |
| Zdroj: | JAAD Case Reports |
| ISSN: | 2352-5126 |
| Popis: | Rituximab is a human/murine chimeric immunoglobulin monoclonal antibody that binds to CD20, a B-cell lymphocyte transmembrane protein. Rituximab been used in the treatment of various hematologic malignancies.1 More recently, rituximab was found to have utility in treating pemphigus vulgaris (PV). The US Food and Drug Administration approved its use in 2018 for treatment of moderate-to-severe pemphigus vulgaris following a randomized trial that demonstrated superior efficacy and fewer adverse events when used in conjunction with prednisone compared with prednisone alone.2,3 As an immunomodulator, rituximab carries a black box warning for potentially fatal infusion reactions, severe mucocutaneous reactions, hepatitis B virus reactivation, and progressive multifocal leukoencephalopathy (PML).2 Rarely, rituximab has been associated with cerebral toxoplasmosis infection.4, 5, 6, 7 Here we present a case of cerebral toxoplasmosis infection in a patient treated with rituximab for pemphigus vulgaris, along with a brief review of central nervous system (CNS) toxoplasmosis in the setting of rituximab therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|